Boldenone Undecylenate (EQ) can provide a mild anti-estrogenic effect when stacked with Testosterone Enanthate, but only to a limited degree — and it’s often not enough on its own to fully control estrogen-related side effects in moderate to high testosterone cycles.

How EQ May Reduce Estrogenic Activity
1. Very Low Aromatization Rate
EQ aromatizes to estrogen at about 50% the rate of testosterone.
This can help balance the estrogen load when EQ is stacked with high-testosterone doses (e.g., 400–600 mg/week Test E).
2. Possible Aromatase Competition (theory)
Some users believe EQ may compete for the aromatase enzyme, slightly reducing how much testosterone is converted to estrogen.
This is speculative and not conclusively proven in humans.
3. Conversion to Dihydroboldenone (DHB)
This non-estrogenic metabolite may create a mild anti-estrogenic environment, though again, the effect is subtle.
EQ does not block estrogen receptors (like Nolvadex) or inhibit aromatase strongly (like Arimidex or Aromasin).
If you're running:
Moderate test (≤300–400 mg/week) + EQ — some users get by without an AI
High test (500–750+ mg/week) + EQ — you’ll likely still need a low-dose AI (e.g., 0.25–0.5 mg Arimidex 2–3x/week)
EQ has mild anti-estrogenic properties, mostly by reducing the overall aromatization burden when stacked with test.
It is not a replacement for an aromatase inhibitor, especially at higher testosterone doses or in sensitive individuals.
Bloodwork (estradiol via sensitive E2 test) is the only reliable way to adjust AI dosage.